Do analysts recommend JATT or FHTX?

Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 115.67%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Foghorn Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has stronger earnings and valuation, JATT or FHTX?

JATT Acquisition has higher earnings, but lower revenue than Foghorn Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Foghorn Therapeutics $30.91M 10.06 -$74.28M -$1.16 N/A

Do analysts prefer JATT or IMRX?

Immuneering has a consensus price target of $17.57, indicating a potential upside of 297.54%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Immuneering 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has stronger earnings & valuation, JATT or IMRX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is JATT or IMRX more profitable?

Immuneering's return on equity of -31.93% beat JATT Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Immuneering N/A -31.93% -29.92%

Do analysts rate JATT or PALI?

Palisade Bio has a consensus target price of $8.83, indicating a potential upside of 347.26%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, JATT or PALI?

JATT Acquisition has higher earnings, but lower revenue than Palisade Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Palisade Bio $250K 1,371.28 -$16.78M -$1.01 N/A

Is JATT or PALI more profitable?

Palisade Bio's return on equity of -36.79% beat JATT Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Palisade Bio N/A -36.79% -34.34%

Do analysts rate SNDL or JATT?

SNDL presently has a consensus target price of $5.00, suggesting a potential upside of 289.11%. Given SNDL's stronger consensus rating and higher probable upside, analysts clearly believe SNDL is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SNDL 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, SNDL or JATT?

JATT Acquisition has lower revenue, but higher earnings than SNDL. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SNDL $677.32M 0.49 -$11.29M -$0.03 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Is SNDL or JATT more profitable?

JATT Acquisition has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat JATT Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets SNDL -1.19% -1.02% -0.85% JATT Acquisition N/A -49.58% 2.84%

Which has higher valuation & earnings, ZNTL or JATT?

JATT Acquisition has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zentalis Pharmaceuticals $67.43M 5.57 -$137.06M -$1.73 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Is ZNTL or JATT more profitable?

JATT Acquisition's return on equity of -49.58% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -53.61% -40.67% JATT Acquisition N/A -49.58% 2.84%

JATT Acquisition (JATT) Competitors

$12.62 +1.62 (+14.68%)

As of 12:42 PM Eastern

Compare

JATT vs. FHTX, IMRX, PALI, SNDL, and ZNTL

Should you buy JATT Acquisition stock or one of its competitors? MarketBeat compares JATT Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with JATT Acquisition include Foghorn Therapeutics (FHTX), Immuneering (IMRX), Palisade Bio (PALI), SNDL (SNDL), and Zentalis Pharmaceuticals (ZNTL). These companies are all part of the "pharmaceutical products" industry.

How does JATT Acquisition compare to Foghorn Therapeutics?

JATT Acquisition (NYSE:JATT) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, Foghorn Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Foghorn Therapeutics and 0 mentions for JATT Acquisition. Foghorn Therapeutics' average media sentiment score of 0.88 beat JATT Acquisition's score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Neutral
Foghorn Therapeutics	Positive

JATT Acquisition has higher earnings, but lower revenue than Foghorn Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Foghorn Therapeutics	$30.91M	10.06	-$74.28M	-$1.16	N/A

JATT Acquisition has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Foghorn Therapeutics has a consensus target price of $11.43, indicating a potential upside of 115.67%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Foghorn Therapeutics beats JATT Acquisition on 9 of the 13 factors compared between the two stocks.

How does JATT Acquisition compare to Immuneering?

JATT Acquisition (NYSE:JATT) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Immuneering has a consensus price target of $17.57, indicating a potential upside of 297.54%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuneering's return on equity of -31.93% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Immuneering	N/A	-31.93%	-29.92%

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 22.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Immuneering had 5 more articles in the media than JATT Acquisition. MarketBeat recorded 5 mentions for Immuneering and 0 mentions for JATT Acquisition. Immuneering's average media sentiment score of 0.70 beat JATT Acquisition's score of 0.00 indicating that Immuneering is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Neutral
Immuneering	Positive

Summary

Immuneering beats JATT Acquisition on 9 of the 11 factors compared between the two stocks.

How does JATT Acquisition compare to Palisade Bio?

JATT Acquisition (NYSE:JATT) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Palisade Bio's return on equity of -36.79% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Palisade Bio	N/A	-36.79%	-34.34%

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 0.1% of Palisade Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

JATT Acquisition has higher earnings, but lower revenue than Palisade Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Palisade Bio	$250K	1,371.28	-$16.78M	-$1.01	N/A

In the previous week, Palisade Bio had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Palisade Bio and 0 mentions for JATT Acquisition. Palisade Bio's average media sentiment score of 0.36 beat JATT Acquisition's score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Neutral
Palisade Bio	Neutral

Palisade Bio has a consensus target price of $8.83, indicating a potential upside of 347.26%. Given Palisade Bio's stronger consensus rating and higher probable upside, analysts plainly believe Palisade Bio is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Palisade Bio beats JATT Acquisition on 8 of the 12 factors compared between the two stocks.

How does JATT Acquisition compare to SNDL?

SNDL (NASDAQ:SNDL) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

48.0% of JATT Acquisition shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, SNDL had 6 more articles in the media than JATT Acquisition. MarketBeat recorded 6 mentions for SNDL and 0 mentions for JATT Acquisition. SNDL's average media sentiment score of 0.37 beat JATT Acquisition's score of 0.00 indicating that SNDL is being referred to more favorably in the media.

Company	Overall Sentiment
SNDL	Neutral
JATT Acquisition	Neutral

JATT Acquisition has lower revenue, but higher earnings than SNDL.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SNDL	$677.32M	0.49	-$11.29M	-$0.03	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

SNDL presently has a consensus target price of $5.00, suggesting a potential upside of 289.11%. Given SNDL's stronger consensus rating and higher probable upside, analysts clearly believe SNDL is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

JATT Acquisition has a net margin of 0.00% compared to SNDL's net margin of -1.19%. SNDL's return on equity of -1.02% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SNDL	-1.19%	-1.02%	-0.85%
JATT Acquisition	N/A	-49.58%	2.84%

Summary

SNDL beats JATT Acquisition on 7 of the 12 factors compared between the two stocks.

How does JATT Acquisition compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

JATT Acquisition's return on equity of -49.58% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
JATT Acquisition	N/A	-49.58%	2.84%

JATT Acquisition has lower revenue, but higher earnings than Zentalis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	5.57	-$137.06M	-$1.73	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

Zentalis Pharmaceuticals currently has a consensus price target of $6.14, indicating a potential upside of 16.45%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Zentalis Pharmaceuticals is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

48.0% of JATT Acquisition shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than JATT Acquisition. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 0 mentions for JATT Acquisition. Zentalis Pharmaceuticals' average media sentiment score of 0.52 beat JATT Acquisition's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Positive
JATT Acquisition	Neutral

Summary

Zentalis Pharmaceuticals beats JATT Acquisition on 6 of the 11 factors compared between the two stocks.

Get JATT Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JATT vs. The Competition

Export

Metric	JATT Acquisition	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$101.24M	$351.49M	$6.80B	$23.41B
Dividend Yield	N/A	N/A	2.67%	4.15%
P/E Ratio	N/A	N/A	27.05	30.87
Price / Sales	N/A	201.77	517.90	20.36
Price / Cash	27.08	22.44	26.68	18.81
Price / Book	-23.80	4.87	10.65	4.76
Net Income	$6.85M	-$141.03M	$3.59B	$1.07B
7 Day Performance	17.24%	-0.45%	-0.84%	0.35%
1 Month Performance	18.12%	0.08%	1.42%	1.32%
1 Year Performance	560.47%	43.75%	24.75%	17.55%

JATT Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JATT JATT Acquisition	N/A	$12.62 +14.7%	N/A	+506.8%	$101.24M	N/A	N/A	3
FHTX Foghorn Therapeutics	2.8913 of 5 stars	$5.95 -1.0%	$11.43 +92.1%	-15.3%	$352.87M	$30.91M	N/A	120
IMRX Immuneering	3.264 of 5 stars	$5.11 -4.7%	$16.57 +224.3%	+3.9%	$346.78M	N/A	N/A	60	News Coverage Analyst Downgrade
PALI Palisade Bio	2.2565 of 5 stars	$1.96 -0.5%	$8.83 +350.7%	+154.7%	$341.95M	$250K	N/A	10
SNDL SNDL	3.991 of 5 stars	$1.31 flat	$5.00 +281.7%	-16.9%	$337.19M	$677.32M	N/A	2,751	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:JATT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

JATT Acquisition (JATT) Competitors

JATT vs. FHTX, IMRX, PALI, SNDL, and ZNTL

How does JATT Acquisition compare to Foghorn Therapeutics?

Summary

How does JATT Acquisition compare to Immuneering?

Summary

How does JATT Acquisition compare to Palisade Bio?

Summary

How does JATT Acquisition compare to SNDL?

Summary

How does JATT Acquisition compare to Zentalis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT vs. The Competition

JATT Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

JATT Acquisition (JATT) Competitors

JATT vs. FHTX, IMRX, PALI, SNDL, and ZNTL

How does JATT Acquisition compare to Foghorn Therapeutics?

Does the media refer more to JATT or FHTX?

Which has stronger earnings and valuation, JATT or FHTX?

Is JATT or FHTX more profitable?

Do institutionals and insiders believe in JATT or FHTX?

Do analysts recommend JATT or FHTX?

Summary

How does JATT Acquisition compare to Immuneering?

Which has stronger earnings & valuation, JATT or IMRX?

Do analysts prefer JATT or IMRX?

Is JATT or IMRX more profitable?

Do institutionals & insiders believe in JATT or IMRX?

Does the media favor JATT or IMRX?

Summary

How does JATT Acquisition compare to Palisade Bio?

Is JATT or PALI more profitable?

Do institutionals and insiders believe in JATT or PALI?

Which has higher earnings and valuation, JATT or PALI?

Does the media prefer JATT or PALI?

Do analysts rate JATT or PALI?

Summary

How does JATT Acquisition compare to SNDL?

Do institutionals & insiders have more ownership in SNDL or JATT?

Does the media prefer SNDL or JATT?

Which has higher valuation & earnings, SNDL or JATT?

Do analysts rate SNDL or JATT?

Is SNDL or JATT more profitable?

Summary

How does JATT Acquisition compare to Zentalis Pharmaceuticals?

Is ZNTL or JATT more profitable?

Which has higher valuation & earnings, ZNTL or JATT?

Do analysts prefer ZNTL or JATT?

Do institutionals & insiders hold more shares of ZNTL or JATT?

Does the media refer more to ZNTL or JATT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT vs. The Competition

JATT Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools